Boston Scientific Corporation (NYSE : BSX) entered into an agreement to acquire remaining 84% stake in DeVoro Medical Inc. for approximately $340 million on September 21, 2021. Pursuant to the terms, Boston Scientific will pay an upfront payment of approximately $269 million and up to $67 million upon achievement of certain clinical and regulatory milestones. The transaction is anticipated to close in the fourth quarter of 2021, subject to customary closing conditions. The transaction is expected to be slightly dilutive to earnings per share in 2021. In 2022, the transaction is not expected to impact adjusted EPS and will be slightly dilutive on a GAAP basis due to amortization expense and acquisition-related charges. Wilson Sonsini Goodrich & Rosati, P.C. acted as legal advisor to Devoro Medical, Inc. Doriann H. Cain, Lynn M. Kornfeld, Jason R. Kraus, Robert B. Leonard, Brandon C. Mason, Daniel G. Prokott, Gayle L. Skolnik and Matt Stamski of Faegre Drinker Biddle & Reath LLP acted as a legal advisor to Boston Scientific Corporation. Fried, Frank, Harris, Shriver & Jacobson LLP acted as a legal advisor to Boston Scientific Corporation. Boston Scientific Corporation (NYSE : BSX) completed the acquisition of remaining 84% stake in DeVoro Medical Inc. on November 8, 2021.